STOCK TITAN

Procaps Group Update on Third Quarter Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) Postpones Earnings Conference Call for 3Q23 Results
Positive
  • None.
Negative
  • None.

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)-- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23”). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call.

About Procaps Group

Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

For more information, visit Procaps’ investor relations website investor.procapsgroup.com.

Investor Contact:

Melissa Angelini

ir@procapsgroup.com

investor.procapsgroup.com

Source: Procaps Group, S.A.

FAQ

Why did Procaps Group postpone the earnings conference call for 3Q23 results?

Procaps Group postponed the earnings conference call to a later date after publishing its results for the third quarter and nine months ended September 30, 2023.

When will Procaps Group host the conference call for the 3Q23 results?

Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call.

Procaps Group, S.A. Ordinary Shares

NASDAQ:PROC

PROC Rankings

PROC Latest News

PROC Stock Data

309.14M
17.15M
83.03%
3.19%
0.01%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Luxembourg City

About PROC

procaps group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. we have direct presence in 13 countries in latin america and we have more than 5,000 collaborators working under a sustainable model. we develop, manufacture, and market over-the-counter (otc) and prescription drugs, nutritional supplements and high-potential clinical solutions.